Determinants of Hepatitis A Vaccine Immunity in a Cohort of Human Immunodeficiency Virus-Infected Children Living in Switzerland

Crisinel, Pierre Alex; Posfay‐Barbe, Klara M.; Aebi, Christoph; Cheseaux, Jean‐Jacques; Kahlert, Christian; Rudin, Christoph; Nadal, David; Siegrist, Claire‐Anne

doi:10.1128/cvi.00264-12

Cited by 6 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In children, Gouvea et al observed that HIV‐positive patients and HIV‐exposed children achieved anti‐HAV antibody levels above 20 mUl/mL, having a 100% seroconversion rate after two doses of HAV vaccine . More recently, similar results were found by Crisinel et al and Mena et al, who found response rates of 97% and 73.4%, respectively, after two doses of the vaccine …”

Section: Discussionmentioning

confidence: 99%

Poor response to hepatitis A vaccination in hematopoietic stem cell transplant recipients

Adati

Silva

Sumita

et al. 2020

Transplant Infectious Dis

View full text Add to dashboard Cite

Background Hepatitis A virus (HAV) infection is highly prevalent in developing countries. In countries experiencing a shift from intermediate/high endemicity to low endemicity, the World Health Organization recommends the incorporation of HAV vaccine into the national vaccination calendar for children aged ≥1 year. Since HAV antibodies wane over time, most HSCT revaccination guidelines advise vaccination as optional, following the country recommendation. However, no study has evaluated the serological response to HAV vaccine in allogeneic HSCT recipients. Methods We conducted a prospective study in 46 HSCT recipients who received two doses of inactivated HAV vaccine. Blood samples were taken before vaccination to determine HAV prevalence rates, and before and 4‐6 weeks after the second dose. Specific anti‐HAV antibodies were detected by a competitive commercial enzyme immune assay. Results Patients received the first dose of vaccine at a median of 332.5 (120‐4134) days after HSCT. Median absolute lymphocyte count at vaccination was 1947 (696‐12 500)/mm3. The seroprevalence rate was 93.5% at inclusion. Although safe and well tolerated, the serological response to HAV vaccine in susceptible patients was poor (33%), and no boost effect was observed in seropositive patients. Conclusions In areas with intermediate/high seroprevalence of HAV, serology should be recommended prior to referral to vaccination. The mechanisms of antibody interference and how to overcome T‐cell function deficiency need to be better understood in transplant populations receiving HAV vaccine. Alternative schedules of HAV vaccination should be evaluated in prospective trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Poor response to hepatitis A vaccination in hematopoietic stem cell transplant recipients

Adati

Silva

Sumita

et al. 2020

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…Despite a high seroconversion rate, children with CD4 counts of <750/mm 3 have lower anti-HAV antibodies, which could reflect less lasting protection. For this reason, serological monitoring and additional boosting doses should be considered for these children [38].…”

Section: Hepatitis a Virusmentioning

confidence: 99%

Living with HIV and Getting Vaccinated: A Narrative Review

et al. 2023

View full text Add to dashboard Cite

After 40 years of its appearance, human immunodeficiency virus (HIV) infection remains a leading public health challenge worldwide. Since the introduction of antiretroviral treatment (ART), HIV infection has become a chronic condition, and people living with HIV could have life expectancies close to those of the general population. People with HIV often have an increased risk of infection or experience more severe morbidity following exposure to vaccine-preventable diseases. Nowadays, several vaccines are available against bacteria and viruses. However, national and international vaccination guidelines for people with HIV are heterogeneous, and not every vaccine is included. For these reasons, we aimed to perform a narrative review about the vaccinations available for adults living with HIV, reporting the most updated studies performed for each vaccine among this population. We performed a comprehensive literature search through electronic databases (Pubmed—MEDLINE and Embase) and search engines (Google Scholar). We included English peer-reviewed publications (articles and reviews) on HIV and vaccination. Despite widespread use and guideline recommendations, few vaccine trials have been conducted in people with HIV. In addition, not all vaccines are recommended for people with HIV, especially for those with low CD4 cells count. Clinicians should carefully collect the history of vaccinations and patients’ acceptance and preferences and regularly check the presence of antibodies for vaccine-preventable pathogens.

show abstract

Vaccination of Human Immunodeficiency Virus–Infected Persons

Sutcliffe¹,

Moss²

2018

Plotkin's Vaccines

View full text Add to dashboard Cite

Determinants of Hepatitis A Vaccine Immunity in a Cohort of Human Immunodeficiency Virus-Infected Children Living in Switzerland

Cited by 6 publications

References 37 publications

Poor response to hepatitis A vaccination in hematopoietic stem cell transplant recipients

Poor response to hepatitis A vaccination in hematopoietic stem cell transplant recipients

Living with HIV and Getting Vaccinated: A Narrative Review

Vaccination of Human Immunodeficiency Virus–Infected Persons

Contact Info

Product

Resources

About